Core Viewpoint - CytomX Therapeutics, Inc. has announced a proposed public offering of up to $250 million to support the development of its pipeline, including the promising Varseta-M program [1][2] Group 1: Offering Details - The public offering includes common stock and pre-funded warrants, with an option for underwriters to purchase an additional $37.5 million in shares [1] - The offering is managed by Jefferies, Piper Sandler, Cantor, and Barclays, with Wedbush PacGrow as co-manager [2] - A shelf registration statement was filed with the U.S. Securities and Exchange Commission, effective immediately [2] Group 2: Pipeline and Collaborations - CytomX's pipeline features Varseta-M, an antibody-drug conjugate targeting EpCAM for advanced colorectal cancer, developed in collaboration with ImmunoGen [2] - Another candidate, CX-801, is a masked interferon alpha-2b PROBODY® cytokine targeting metastatic melanoma [2] - The company has strategic collaborations with Amgen, Bristol Myers Squibb, Regeneron, and Moderna [3] Group 3: Financial Performance and Market Reaction - The stock experienced high volatility following the offering announcement and positive Phase 1 data for Varseta-M, which showed confirmed response rates of 32% at 10 mg/kg and 20% at 8.6 mg/kg [3] - As of March 17, 2026, CTMX trades around $5.82–$6.53, with a market capitalization of approximately $400 million [4] - Trading volume was extremely high, with over 121 million shares traded on March 16, driven by the offering news and earnings update [4]